FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068671678> ?p ?o ?g. }

• W2068671678 endingPage "268" @default.
• W2068671678 startingPage "261" @default.
• W2068671678 abstract "Mannan, a polysaccharide preparation from Saccharomyces cerevisiae, has previously been shown to enhance influenza virus replication in mice by inhibiting host defense collectins. The use of mannan in infections may serve to broaden the types of influenza viruses that can be studied in rodent infection models. When mannan was co-administered with influenza B/Sichuan/379/99 virus to mice, the animals died from the infection, whereas mice infected with only virus survived. Three types of influenza A (H1N1) and another influenza B (Hong Kong/330/01) virus infection were also enhanced by mannan, but not four types of influenza A (H3N2) viruses. Mannan was used at 0.16 or 0.5 mg/mouse for optimal disease-enhancing activity using influenza B/Sichuan/379/99 virus. Using this model, influenza B/Sichuan/379/99 infections were treated with oseltamivir, ribavirin or viramidine (the carboxamidine derivative of ribavirin). When oral gavage treatments started 4 h before virus and mannan challenge, oseltamivir was effective at 2.5, 5 and 10 mg/kg/day. Ribavirin was active at 20, 40 and 80 mg/kg/day. Viramidine was effective at 80 and 160 mg/kg/day but not at 40 mg/kg/day. Active drug doses improved lung consolidation scores and lung weights, with decreases in lung virus titres also noted. Arterial oxygen saturation values in treated groups were significantly better than those of the placebo group on days 7-11 of the infection. Oseltamivir (5 mg/kg/day) and ribavirin (40 mg/kg/day) were used alone and in combination to determine how late after infection they could be beneficially administered. Ribavirin alone was very effective (90-100% survival of mice) when treatments started as late as 3 days after infection. Forty percent survival was evident even when treatments started 4 days post-infection. Oseltamivir was active starting treatments 1 day after virus exposure, but lost considerable efficacy when treatments began after that time. The combination of ribavirin and oseltamivir appeared to be no better than ribavirin alone, due to the stronger beneficial effect of ribavirin in this model. The overall results demonstrate that mannan can be used to enhance certain non-lethal influenza virus infections sufficiently to allow antiviral studies." @default.
• W2068671678 created "2016-06-24" @default.
• W2068671678 creator A5020732425 @default.
• W2068671678 creator A5021948435 @default.
• W2068671678 creator A5031975164 @default.
• W2068671678 creator A5046546484 @default.
• W2068671678 creator A5082996108 @default.
• W2068671678 date "2004-10-01" @default.
• W2068671678 modified "2023-10-16" @default.
• W2068671678 title "Treatment of Mannan-Enhanced Influenza B Virus Infections in Mice with Oseltamivir, Ribavirin and Viramidine" @default.
• W2068671678 cites W1792322686 @default.
• W2068671678 cites W1964197382 @default.
• W2068671678 cites W1974519240 @default.
• W2068671678 cites W1974937210 @default.
• W2068671678 cites W2007625323 @default.
• W2068671678 cites W2013789691 @default.
• W2068671678 cites W2015845113 @default.
• W2068671678 cites W2030575353 @default.
• W2068671678 cites W2042080893 @default.
• W2068671678 cites W2046667560 @default.
• W2068671678 cites W2050299848 @default.
• W2068671678 cites W2053414783 @default.
• W2068671678 cites W2055986785 @default.
• W2068671678 cites W2057407143 @default.
• W2068671678 cites W2058290736 @default.
• W2068671678 cites W2060735817 @default.
• W2068671678 cites W2074681797 @default.
• W2068671678 cites W2105466816 @default.
• W2068671678 cites W2113968522 @default.
• W2068671678 cites W2124857355 @default.
• W2068671678 cites W2126352919 @default.
• W2068671678 cites W2134671802 @default.
• W2068671678 cites W2136685402 @default.
• W2068671678 cites W2151174475 @default.
• W2068671678 cites W2157087130 @default.
• W2068671678 cites W2169666280 @default.
• W2068671678 cites W2169861418 @default.
• W2068671678 cites W2169914007 @default.
• W2068671678 cites W2270258930 @default.
• W2068671678 doi "https://doi.org/10.1177/095632020401500505" @default.
• W2068671678 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15535048" @default.
• W2068671678 hasPublicationYear "2004" @default.
• W2068671678 type Work @default.
• W2068671678 sameAs 2068671678 @default.
• W2068671678 citedByCount "13" @default.
• W2068671678 countsByYear W20686716782012 @default.
• W2068671678 countsByYear W20686716782013 @default.
• W2068671678 countsByYear W20686716782014 @default.
• W2068671678 countsByYear W20686716782018 @default.
• W2068671678 countsByYear W20686716782023 @default.
• W2068671678 crossrefType "journal-article" @default.
• W2068671678 hasAuthorship W2068671678A5020732425 @default.
• W2068671678 hasAuthorship W2068671678A5021948435 @default.
• W2068671678 hasAuthorship W2068671678A5031975164 @default.
• W2068671678 hasAuthorship W2068671678A5046546484 @default.
• W2068671678 hasAuthorship W2068671678A5082996108 @default.
• W2068671678 hasConcept C100817775 @default.
• W2068671678 hasConcept C126322002 @default.
• W2068671678 hasConcept C159047783 @default.
• W2068671678 hasConcept C203014093 @default.
• W2068671678 hasConcept C2522874641 @default.
• W2068671678 hasConcept C2776408679 @default.
• W2068671678 hasConcept C2777538117 @default.
• W2068671678 hasConcept C2777546802 @default.
• W2068671678 hasConcept C2779134260 @default.
• W2068671678 hasConcept C2779719659 @default.
• W2068671678 hasConcept C2779756493 @default.
• W2068671678 hasConcept C2780040827 @default.
• W2068671678 hasConcept C2780374985 @default.
• W2068671678 hasConcept C2781416681 @default.
• W2068671678 hasConcept C3008058167 @default.
• W2068671678 hasConcept C524204448 @default.
• W2068671678 hasConcept C55493867 @default.
• W2068671678 hasConcept C71924100 @default.
• W2068671678 hasConcept C86803240 @default.
• W2068671678 hasConcept C89423630 @default.
• W2068671678 hasConceptScore W2068671678C100817775 @default.
• W2068671678 hasConceptScore W2068671678C126322002 @default.
• W2068671678 hasConceptScore W2068671678C159047783 @default.
• W2068671678 hasConceptScore W2068671678C203014093 @default.
• W2068671678 hasConceptScore W2068671678C2522874641 @default.
• W2068671678 hasConceptScore W2068671678C2776408679 @default.
• W2068671678 hasConceptScore W2068671678C2777538117 @default.
• W2068671678 hasConceptScore W2068671678C2777546802 @default.
• W2068671678 hasConceptScore W2068671678C2779134260 @default.
• W2068671678 hasConceptScore W2068671678C2779719659 @default.
• W2068671678 hasConceptScore W2068671678C2779756493 @default.
• W2068671678 hasConceptScore W2068671678C2780040827 @default.
• W2068671678 hasConceptScore W2068671678C2780374985 @default.
• W2068671678 hasConceptScore W2068671678C2781416681 @default.
• W2068671678 hasConceptScore W2068671678C3008058167 @default.
• W2068671678 hasConceptScore W2068671678C524204448 @default.
• W2068671678 hasConceptScore W2068671678C55493867 @default.
• W2068671678 hasConceptScore W2068671678C71924100 @default.
• W2068671678 hasConceptScore W2068671678C86803240 @default.
• W2068671678 hasConceptScore W2068671678C89423630 @default.
• W2068671678 hasIssue "5" @default.
• W2068671678 hasLocation W20686716781 @default.

• next